Retatrutide, an experimental weight-loss drug that could compete against blockbusters Wegovy and Zepbound, may work wonders for obese folks with liver disease, new research shows.
A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday.
While many have raved about the powers of popular weight-loss drugs like Wegovy and Ozempic, new research confirms the medications can trigger some nasty gastrointestinal side effects.